What is SouthernBiotech?
SouthernBiotech, founded in 1982, is a key provider of high-quality antibodies essential for a range of research applications, including diagnostics, drug development, and discovery studies. The company boasts an extensive catalog of primary and secondary antibodies, immunoreagents, and offers custom services designed to meet specific researcher needs. Their commitment to customer success is evident in their flexible, customizable solutions and responsive support, underpinned by in-house production and validation processes that ensure product reliability and timely delivery.
How much funding has SouthernBiotech raised?
SouthernBiotech has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
Key Investors in SouthernBiotech
PPP
Public-Private Partnership
What's next for SouthernBiotech?
The substantial large-scale late-stage funding context suggests SouthernBiotech is poised for significant expansion and further development of its product lines and service offerings. This strategic investment will likely fuel advancements in their antibody technology, potentially broadening their reach into new therapeutic areas or enhancing their diagnostic capabilities. The company's long history and focus on quality position it well to capitalize on emerging opportunities in the rapidly evolving biotechnology landscape.
See full SouthernBiotech company page
